Fella Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20/S21 men's GLP-1 obesity telemedicine at $50M+ ARR cashflow positive 24 months with $130K total raised; competing with Ro and Hims for men's obesity treatment at massive capital efficiency targeting 1M patients by end 2026.
About
Fella Health is a San Francisco-based men's obesity telemedicine platform — bootstrapped with minimal external funding ($130,000 seed from Y Combinator, Global Founders Capital, AngelList, and founders of Indeed, Curative, and Alan) — providing men with obesity and metabolic health challenges with a subscription-based direct-to-patient treatment program combining FDA-approved GLP-1 medications (semaglutide and tirzepatide), psychological strengthening, and behavioral interventions for significant weight loss and metabolic health improvement. Having achieved over $50 million in annual recurring revenue and cashflow positive operations for 24 months, with 76+ employees and a mission to serve 1 million men by end of 2026, Fella also operates Delilah Health for women through the same clinical model. Y Combinator W20/S21 backed.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.